198 related articles for article (PubMed ID: 33822480)
1. Central nervous system relapse in a child with anaplastic large cell lymphoma: potential for new therapeutic strategies.
Raffa EH; Branson HM; Ngan B; Alexander S; Abla O
Cancer Rep (Hoboken); 2021 Oct; 4(5):e1377. PubMed ID: 33822480
[TBL] [Abstract][Full Text] [Related]
2. CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series.
Ruf S; Hebart H; Hjalgrim LL; Kabickova E; Lang P; Steinbach D; Schwabe GC; Woessmann W
Pediatr Blood Cancer; 2018 Jun; 65(6):e27003. PubMed ID: 29512859
[TBL] [Abstract][Full Text] [Related]
3. Isolated central nervous system (CNS) relapse in a case of childhood systemic anaplastic large cell lymphoma without initial CNS involvement.
Mori T; Sugita K; Kimura K; Fuke T; Miura T; Kiyokawa N; Fujimoto J
J Pediatr Hematol Oncol; 2003 Dec; 25(12):975-7. PubMed ID: 14663283
[TBL] [Abstract][Full Text] [Related]
4. Neuro-meningeal relapse in anaplastic large-cell lymphoma: incidence, risk factors and prognosis - a report from the European intergroup for childhood non-Hodgkin lymphoma.
Del Baldo G; Abbas R; Woessmann W; Horibe K; Pillon M; Burke A; Beishuizen A; Rigaud C; Le Deley MC; Lamant L; Brugières L
Br J Haematol; 2021 Mar; 192(6):1039-1048. PubMed ID: 32648260
[TBL] [Abstract][Full Text] [Related]
5. Isolated Central Nervous System Progression During Systemic Treatment With Brentuximab Vedotin Monotherapy in a Pediatric Patient With Recurrent ALK-negative Anaplastic Large Cell Lymphoma.
Kim Y; Sudo A; Oyama R; Keino D; Tomizawa D; Kato M; Osumi T; Mori T
J Pediatr Hematol Oncol; 2021 Aug; 43(6):e864-e866. PubMed ID: 32769561
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab Vedotin and High-dose Methotrexate Administrated Alternately for Refractory Anaplastic Large-cell Lymphoma With Central Nervous System Disease.
Mitsunobu T; Nishikawa T; Kusuda M; Nakagawa S; Kodama Y; Okamoto Y; Kawano Y
J Pediatr Hematol Oncol; 2020 Aug; 42(6):e456-e458. PubMed ID: 31274669
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
8. Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma.
Wang X; Wu J; Zhang M
Hematology; 2019 Dec; 24(1):440-445. PubMed ID: 31072226
[TBL] [Abstract][Full Text] [Related]
9. High-dose methotrexate monotherapy followed by radiation for CD30-positive, anaplastic lymphoma kinase-1-positive anaplastic large-cell lymphoma in the brain of a child.
Furuya K; Takanashi S; Ogawa A; Takahashi Y; Nakagomi T
J Neurosurg Pediatr; 2014 Sep; 14(3):311-5. PubMed ID: 25014324
[TBL] [Abstract][Full Text] [Related]
10. The biology and management of systemic anaplastic large cell lymphoma.
Hapgood G; Savage KJ
Blood; 2015 Jul; 126(1):17-25. PubMed ID: 25869285
[TBL] [Abstract][Full Text] [Related]
11. Future Perspective for ALK-Positive Anaplastic Large Cell Lymphoma with Initial Central Nervous System (CNS) Involvement: Could Next-Generation ALK Inhibitors Replace Brain Radiotherapy for the Prevention of Further CNS Relapse?
Tanaka M; Miura H; Ishimaru S; Furukawa G; Kawamura Y; Kozawa K; Yamada S; Ito F; Kudo K; Yoshikawa T
Pediatr Rep; 2023 May; 15(2):333-340. PubMed ID: 37368362
[TBL] [Abstract][Full Text] [Related]
12. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk.
Ait-Tahar K; Damm-Welk C; Burkhardt B; Zimmermann M; Klapper W; Reiter A; Pulford K; Woessmann W
Blood; 2010 Apr; 115(16):3314-9. PubMed ID: 20185586
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
14. Brain metastasis of ALK positive anaplastic large cell lymphoma after a long-term disease free survival in an old adult.
Wang CX; Wang H; Li J; Ma HH; Yu B; Shi SS; Zhou XJ; Shi QL
Int J Clin Exp Pathol; 2014; 7(3):1182-7. PubMed ID: 24696735
[TBL] [Abstract][Full Text] [Related]
15. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
Savage KJ; Harris NL; Vose JM; Ullrich F; Jaffe ES; Connors JM; Rimsza L; Pileri SA; Chhanabhai M; Gascoyne RD; Armitage JO; Weisenburger DD;
Blood; 2008 Jun; 111(12):5496-504. PubMed ID: 18385450
[TBL] [Abstract][Full Text] [Related]
16. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic large cell lymphoma, ALK-positive.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2012 Aug; 83(2):293-302. PubMed ID: 22440390
[TBL] [Abstract][Full Text] [Related]
18. CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma.
Shen J; Medeiros LJ; Li S; Wang SA; Lin P; Khanlari M; Iyer SP; Yin CC; Tang G; Jorgensen JL; Hu S; Miranda RN; Xu J
Hum Pathol; 2020 Apr; 98():1-9. PubMed ID: 32032618
[TBL] [Abstract][Full Text] [Related]
19. Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases.
Agrawal K; Shet T; Sridhar E; Dhende S; Sengar M; Arora B; Laskar S; Gujral S; Menon H; Banavali S
Indian J Pathol Microbiol; 2017; 60(4):533-540. PubMed ID: 29323068
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan.
Iwafuchi H; Nakazawa A; Sekimizu M; Mori T; Osumi T; Iijima-Yamashita Y; Ohki K; Kiyokawa N; Fukano R; Saito AM; Horibe K; Kobayashi R;
Hum Pathol; 2021 Oct; 116():112-121. PubMed ID: 34363798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
